Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 13Terminated 6Unknown 5Recruiting 5Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5NET 3

Conditions

Neuroendocrine Tumors 3Pituitary Neoplasms 1Neoplasm Metastasis 1Growth Hormone-Secreting Pituitary Adenoma 1Carcinoid Tumor 1Acromegaly 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Interventional × lanreotide × Clear all
NCT04427787 2021-09-05

LOLA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
69 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02823691 2021-06-07

MetNET-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase EARLY_PHASE1 Unknown
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03083210 2019-05-20

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Samsung Medical Center

Phase 4 Unknown
28 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03439709 2018-03-01

MERGE

Samsung Medical Center

Phase 3 Unknown
90 enrolled
Endocrine

Acromegaly, Pituitary Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT01731925 2017-01-31

SUNLAND

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Unknown
44 enrolled
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡